Endonovo Therapeutics Inc (OTCMKTS:ENDV) is trading strong just over its established support levels at $0.10 on moderate volume. The stock has a history of strong moves running as high as $0.999 earlier this year.
The initial move up on ENDV came after the Company announced they are developing a next-generation, off-the-shelf treatment for Graft-Versus-Host Disease (GVHD) using Cytotronics(TM) expanded and ex vivo enhanced stem cells from the human umbilical cord.
Endonovo Therapeutics Inc (OTCMKTS:ENDV) is an innovative biotechnology company developing bioelectronic devices and therapies for regenerative medicine. Endonovo’s Immunotronics(TM) platform is a non-invasive, non-implantable bioelectronic device for treating/preventing vital organ failure through the reduction of inflammation, cell death and the promotion of regeneration.
Endonovo’s Cytotronics(TM) platform provides for a method of expanding and enhancing the biological and therapeutic properties of cells for the development of next-generation cell therapies. The Company’s initial concentration is on the treatment of acute and chronic inflammatory conditions of the liver using its proprietary Immunotronics(TM) platform and the treatment of Graft-Versus-Host Disease using its ex vivo expanded and enhanced stem cells.
Earlier this year ENDV announced the development of a large-scale method for the expansion of umbilical cord blood. ENDV says their technology could allow for a 10x increase in adult stem cell transplants and potentially increase the safety of these treatments by allowing for the expansion of sub-optimal cord blood products that are better matched to patients.
Endonovo’s technology consists of the co-culturing of cord blood mononuclear cells with a portion of the umbilical cord in a three-dimensional rotating wall vessel (RWV) bioreactor, allowing for the expansion of hematopoietic stem cells. The expanded cord blood products would meet the minimal cell requirements for the use of cord blood in adults and potentially result in enhanced engraftment and less toxicities, such as graft versus host disease (GVHD) that occur in lower level HLA matched cord blood units.
To Find out the inside Scoop on ENDV Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
In October ENDV announced two bioelectronic-based platforms for regenerative medicine: Immunotronics(TM), a non-invasive and non-implantable immuno-regulatory device designed to treat inflammatory conditions in vital organs, including acute organ failure; and Cytotronics(TM), a proprietary bioelectronic-based method of expanding and manipulating cells for the creation of cell therapies and tissue engineering.
Endonovo is concentrating its efforts on inflammatory conditions in vital organs and previously announced it’s in the pre-clinical phase of assessing its proprietary Immunotronic technology in the treatment of chronic and acute inflammatory conditions in the liver, including fulminant liver failure.
In November ENDV announced it is developing a next-generation, off-the-shelf treatment for Graft-Versus-Host Disease (GVHD) using Cytotronics(TM) expanded and ex vivo enhanced stem cells from the human umbilical cord. Endonovo Chief Scientist, Dr. Donnie Rudd said “We have taken our method of expanding a population of immune privileged stem cells from the human umbilical cord and combined it with our Cytotronics platform to create large quantities of optimized immuno-regulatory stem cells that can be used as an allogeneic, off-the-shelf therapy for the treatment of Graft-Versus-Host Disease. Our Cytotronics platform is particularly suited to address many of the issues that have plagued stem cell therapies that have recently failed, such as their loss of potency and self-renewal when expanded ex vivo, their poor engraftment and their limited ability to survive when transplanted,” says Dr. Rudd.
On August 19 ENDV announced the binding letter agreement (LOI) to acquire Rio Grande Neurosciences (RGN), announced on July 11, 2016 has been dissolved effective today. The Company will not be proceeding with the acquisition.
The binding LOI was terminated by RGN’s CEO following its request to renegotiate the terms of the binding-LOI, including the aggregate purchase price and the removal of non-solicitation of the binding letter agreement. Our board of directors has determined we are better served by this decision. As a result, the $500,000 note issued to RGN by Endonovo as an initial payment has been cancelled.
We have a Monster Pick Coming. Subscribe Right Now!
Currently trading at a $17 million market valuation ENDV has minimal assets or revenues and fast rising debt that could lead to dilution. But ENDV is an exciting story in small caps; the Company is developing bioelectronics-based products and therapies for regenerative medicine and just retained Holland & Knight to prepare and file the paperwork necessary to obtain an orphan drug designation. Stem cells have always been an explosive sector and ENDV is always one licensing, royalty deal or JV away from a parabolic move. The stock has shown us already is has runner in its blood. We will be updating on ENDV when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with ENDV.
Sign Up now for our 100% FREE Penny Stock Newsletter
Disclosure: we hold no position in ENDV either long or short and we have not been compensated for this article.